Pfizer’s PARP inhibitor successful in phase III study in metastatic prostate cancer
ADC评论
October 6, 2022
On October 4, Pfizer announced that the oral PARP inhibitor Talzenna (talazoparib) combined with Xtandi (enzalutamide) in the treatment of male patients with metastatic castration-resistant
